SCHEMBL5651774

SCHEMBL5651774

CCOC(=O)CSc1ncccc1C(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.58
ALDH1A1 P00352 4/20 0.58
L3MBTL1 Q9Y468 4/20 0.55
HSD17B10 Q99714 2/20 0.52
HTT P42858 2/20 0.52
TP53 P04637 2/20 0.52
KDM4E B2RXH2 1/20 0.52
HPGD P15428 1/20 0.52
PRNP P04156 6/20 0.52
RXFP1 Q9HBX9 5/20 0.52
CYP1A2 P05177 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
POLB P06746 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
MAPT P10636 2/20 0.50
TSHR P16473 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14315170 0.84 ALDH1A1 (0.70) LMNAALDH1A1L3MBTL1HSD17B10HTT
SCHEMBL10521309 0.77 SMN1; SMN2 (0.57) ALDH1A1L3MBTL1TP53CYP2C9SMN1; SMN2
SCHEMBL4126057 0.76 HSD17B10 (0.69) LMNAALDH1A1L3MBTL1HSD17B10HTT
Hydrochloric Acid SCHEMBL10755615 0.76 SMN1; SMN2 (0.56) ALDH1A1L3MBTL1TP53CYP2C9SMN1; SMN2
SCHEMBL10761269 0.76 SMN1; SMN2 (0.56) LMNAALDH1A1L3MBTL1TP53CYP1A2
SCHEMBL14398958 0.76 HTT (0.59) LMNAALDH1A1L3MBTL1HSD17B10HTT
SCHEMBL10704988 0.76 SMN1; SMN2 (0.56) ALDH1A1L3MBTL1HTTTP53KDM4E
SCHEMBL10708467 0.75 SMN1; SMN2 (0.52) ALDH1A1L3MBTL1TP53CYP2C9SMN1; SMN2
Hydrochloric Acid SCHEMBL10709402 0.75 SMN1; SMN2 (0.55) ALDH1A1L3MBTL1HTTTP53KDM4E
Hydrochloric Acid SCHEMBL10760840 0.74 SMN1; SMN2 (0.51) ALDH1A1L3MBTL1TP53CYP2C9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed
EP-1438313-A1 BICYCLIC OXOPYRIDINE AND OXOPYRIMIDINE DERIVATIVES Celltech R & D Limited (GB) 2004-07-21 EP disclosed
WO-2003033502-A1 BICYCLIC OXOPYRIDINE AND OXOPYRIMIDINE DERIVATIVES CELLTECH R & D LIMITED (GB) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 LMNA 1417/4885ALDH1A1 1498/4885L3MBTL1 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.